Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Cancer Genetics

Cancer Genetics
1999 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
CGIX STOCK SYMBOL
4 INVESTMENTS
$4.85 SHARE PRICE (As of Friday Closing)
Description

Cancer Genetics Inc is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular markers. The company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. It also enables biotech and pharmaceutical companies to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company derives most of its revenue from the United States.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
NAS
Primary Office
  • Meadows Office Complex
  • 201 Route 17 North, 2nd Floor
  • Rutherford, NJ 07070
  • United States

+1 (201) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Cancer Genetics’s full profile, request a free trial.

Cancer Genetics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.00 - $11.70 $10.2M $4.88 -$7.77 686K 2.1M

Cancer Genetics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 9,111 17,350 54,471 20,230
Revenue 29,643 27,470 29,121 27,049
EBITDA (19,531) (16,160) (18,729) (12,997)
Net Income (10,180) (20,373) (20,880) (15,803)
Total Assets 20,836 35,406 52,221 42,434
Total Debt 2,717 11,811 11,033 5,137
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cancer Genetics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Cancer Genetics‘s full profile, request access.

Request full access to PitchBook

Cancer Genetics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Cancer Genetics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Cancer Genetics Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Admera Health Venture Capital-Backed South Plainfield, NJ 00 00000000000
0000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
000000000 00000000 Venture Capital-Backed Espoo, Finland 000 000.00 00000 00000
000 0000000 000000 Corporation Bar Harbor, ME 0000 0000000000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Cancer Genetics Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 15-Aug-2017 000000000000000000 00.00 Other Pharmaceuticals and Biotechnology 00000 000000
00000000 00000000 09-Oct-2015 000000000000000000 000.00 Diagnostic Equipment 000000 00000
0000000 16-Jul-2014 000000000000000000 00.000 Practice Management (Healthcare) 00000 000000
Cancer Genetics India 15-May-2014 Merger/Acquisition 00.00 Laboratory Services (Healthcare) 00000 000000
To view this company’s complete investment and acquisition history, request access »

Cancer Genetics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000 00 15-May-2014 000000000000000000 00.00 Completed
  • 000000 00000000
To view this company’s complete exits history, request access »

Cancer Genetics Subsidiaries (2)

Company Name Industry Location Founded
vivoPharm Other Pharmaceuticals and Biotechnology Bundoora, Australia 2003
0000000 Practice Management (Healthcare) Morrisville, NC 0000
To view this company’s complete subsidiary history, request access »

Cancer Genetics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Cancer Genetics‘s full profile, request access.

Request full access to PitchBook

Cancer Genetics Executive Team (15)

Name Title Board
Seat
Contact
Info
John Roberts Chief Executive Officer & President
Glenn Miles Chief Financial Officer
Lan Wang Medical Director
Michael McCartney Executive

11 Former Executives

You’re viewing 4 of 15 executives. Get the full list »

Cancer Genetics Board Members (7)

Name Representing Role Since Contact
Info
Edmund Cannon Self Board Member 000 0000
John Pappajohn Self Chairman Of the Board 000 0000
Raju Chaganti Ph.D Self Board Member 000 0000
Robert Kaufman Self Board Member 000 0000

3 Former Board Members

You’re viewing 4 of 7 board members. Get the full list »